Fangxin Hong

Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Amy Sanders Clark, Fangxin Hong, Richard S. Finn, Angela M. DeMichele et autres

Representativeness of Study Participants

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Matthew James Pianko, Charlotte Pawlyn, Shang‐Yi Huang, Tadao Ishida et autres

BACKGROUND ELRA is a humanized, BCMA/CD3 bispecific antibody. In the phase 2 registrational MagnetisMM-3 (MM-3) trial, SC ELRA given as 2 step-up priming doses (12 mg on day 1 and 32 mg on day 4 of cycle 1) followed by 76 mg …

us, gb, tw, jp, fr (code pays fourni par la source)

Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9.

Douglas Weston Sborov, Charlotte Pawlyn, Tadao Ishida, Jeffrey Huang et autres

7522 Background: Elranatamab (ELRA) is a humanized BCMA-CD3 bispecific antibody. In the phase 2 registrational MagnetisMM-3 (MM-3) trial, SC ELRA was given as 2 step-up priming doses (12 mg on C1D1 and 32 mg on C1D4) followed by 76 mg QW in …

us, gb, jp, tw (code pays fourni par la source)

Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Amy Sanders Clark, Fangxin Hong, Richard S. Finn, Angela M. DeMichele et autres

Representativeness of Study Participants

Data from Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Amy Sanders Clark, Fangxin Hong, Richard S. Finn, Angela M. DeMichele et autres

AbstractPurpose: Cyclin D/CDK4/6 is critical in controlling the G1 to S checkpoint. CCND, the gene encoding cyclin D, is known to be amplified in a variety of solid tumors. Palbociclib is an oral CDK4/6 inhibitor, approved in advanced breast cancer in combination …

us (code pays fourni par la source)

Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Amy Sanders Clark, Fangxin Hong, Richard S. Finn, Angela M. DeMichele et autres

Representativeness of Study Participants

Supplementary Materials and Methods from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

Magda Bahcall, Cloud Peter Paweletz, Yanan Kuang, Luke J. Taus et autres

Application of Bliss independence to test for synergy effect of TKI combination treatment in vivo

Supplementary Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

Magda Bahcall, Cloud Peter Paweletz, Yanan Kuang, Luke J. Taus et autres

Supplementary Figures S1-3; Supplementary Tables S1-3

Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

Magda Bahcall, Cloud Peter Paweletz, Yanan Kuang, Luke J. Taus et autres

Abstract MET-targeted therapies are clinically effective in MET-amplified and MET exon 14 deletion mutant (METex14) non–small cell lung cancers (NSCLCs), but their efficacy is limited by the development of drug resistance. Structurally distinct MET tyrosine kinase inhibitors (TKIs) (type I/II) have been …

Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

Magda Bahcall, Cloud Peter Paweletz, Yanan Kuang, Luke J. Taus et autres

Abstract MET-targeted therapies are clinically effective in MET-amplified and MET exon 14 deletion mutant (METex14) non–small cell lung cancers (NSCLCs), but their efficacy is limited by the development of drug resistance. Structurally distinct MET tyrosine kinase inhibitors (TKIs) (type I/II) have been …

us (code pays fourni par la source)

Supplementary Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

Magda Bahcall, Cloud Peter Paweletz, Yanan Kuang, Luke J. Taus et autres

Supplementary Figures S1-3; Supplementary Tables S1-3

Supplementary Materials and Methods from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

Magda Bahcall, Cloud Peter Paweletz, Yanan Kuang, Luke J. Taus et autres

Application of Bliss independence to test for synergy effect of TKI combination treatment in vivo